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CatecholaminesNegative mood and stress are associated with cardiovascular and metabolic disease. There are likely many
physiological mechanisms underlying the poor health outcomes. The relationship of psychological states
(negative mood, life stress, and stress-responsive hormones) and adiponectin, an adipokine that promotes
insulin sensitivity, was investigated in two separate studies. The two groups of participants included 52 healthy,
premenopausal women, and 63 postmenopausal women with a range of stress levels. The relationship between
adiponectin and psychological state (perceived stress and negative mood) was examined cross-sectionally in
both groups of participants, but also prospectively (1 year later) in the group of postmenopausal women.
In premenopausal women, negative mood and nocturnal urinary epinephrine were signiﬁcantly related to
adiponectin, independent of BMI. In postmenopausal women, negative mood was not associated with
adiponectin cross-sectionally, but negative mood was a signiﬁcant predictor for lower levels of adiponectin 1
year later, independent of initial adiponectin concentrations and changes in body mass index. Lastly, having a
depressivedisorderwas related to lower adiponectin. As adiponectin levels are associatedwith insulin resistance,
obesity, and diabetesmellitus, theseﬁndings suggest theremay be an adiponectin-mediated pathway explaining
in part how negative mood affects metabolic health. Mechanistic studies are needed to explore this potential
relationship further.University of California, 3333
8, USA. Fax: +1 415 476 7744.
lsevier Inc.© 2010 Published by Elsevier Inc.Introduction
Eightypercentof adults,womenmore thanmen, report at least some
stress in their lives (Adam and Epel, 2007). Given the well known
relationship between stress arousal and energy regulation, the
Metabolic Syndrome falls into the realm of stress-related disorders
(Chrousos, 2000b). While the hypothalamus and the brain stem
represent the central control stations of stress regulation, the hypotha-
lamic–pituitary–adrenal (HPA) axis together with the efferent sympa-
thetic/adrenomedullary system are the peripheral limbs, vital for
survival in stressful situations (Habib et al., 2001; Tsigos and Chrousos,
2002). These systemsnot only regulate the stress response, but alsoplay
an important role for energy metabolism. Excess cortisol secretion due
to chronic stressors including job strain (Vitaliano et al., 2002)) and
increased sympathoadrenal activity (Brunner et al., 2002) are associated
with visceral obesity and other features of the metabolic syndrome
(Rosmond, 2005).
Adipose tissue is no longer considered an inert tissue devoted to
energy storage, but is now recognized as an endocrine organ secretinga variety of biologically active components (Kwon et al., 2005). These
secretory products from the adipocyte, labeled as “adipokines,”
include leptin, resistin and adiponectin (Flier, 1995, 2001). Adiponec-
tin, the gene product of the adipose gene transcript 1 (apM1), is a
protein that is exclusively and abundantly expressed in white adipose
tissue (Fantuzzi, 2005)—the larger the adipocyte the lower the
adiponectin production (Swarbrick andHavel, 2008). Low adiponectin
concentrations are associated with insulin resistance, metabolic
disease (Stefan et al., 2002; Weyer et al., 2001), and earlier mortality
(Poehls et al., 2009). In the attempt to understand how stress arousal
may impact obesity-related disease risk, adiponectin may be of
particularly interest. The promoter region of apM1 contains consensus
sequences for glucocorticoid receptor binding and may be inﬂuenced
by environmental ﬂuctuations such as chronic stress (Fernandez-Real
et al., 2003), possibly contributing to the adverse effects of stress on
metabolic parameters such as insulin sensitivity (Chrousos, 2000b).
Indeed, reduced apM1 gene expression and reduced adiponectin
plasma levels are associated with obesity and type 2 diabetes mellitus
in humans (Kern et al., 2003; Kwon et al., 2005; Weyer et al., 2001).
It has been shown that exogenous glucocorticoid administration
decreases adiponectin concentrations transiently in human subjects
(Fallo et al., 2004). In rodents, beta adrenergic agonists reduced
adiponectin in both adipose tissue and blood, suggesting that
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et al., 2002).
A stress-responsive hormone that has been shown to potentially
regulate adipose tissue mass is dehydroepiandrosterone (DHEA)
(Karbowska and Kochan, 2005). DHEA_S is themajor circulating steroid
in humans and is almost exclusively secreted by the cortex of the
adrenal gland (Wolf and Kirschbaum, 1999). It is a precursor hormone
for several bio-active sex steroids such as estradiol and testosterone
(Parker, 1991). DHEA and its sulfate ester (DHEA_S) have fat reducing
properties at least inmales, andmay function as an anti-obesity agent in
various models of obesity (Hansen et al., 1997; Kajita et al., 2003;
Karbowska and Kochan, 2005). The relevance of animal models for
humanDHEA-S research is uncertain, since rodents have noor very little
DHEA-S. DHEA concentrations declinewith age (Orentreich et al., 1984)
and stress (Wolf and Kirschbaum, 1999) and low DHEA has been
associated with various disorders such as insulin resistance, type 2
diabetes and atherosclerosis in males (Herrington et al., 1990;
Yamaguchi et al., 1998). Emerging evidence shows that DHEA's
protective properties may be mediated in part by an up-regulation of
adiponectin gene expression and an increase in adiponectin secretion
from adipose tissue (Karbowska and Kochan, 2005). It has been
hypothesized that adiponectin mediates the relationship between
psychopathology and obesity (Yilmaz, 2008), and one study found a
relationship between lower adiponectin in depressed compared to non-
depressed men and women (Leo et al., 2006).
To our knowledge no research has explored the relationship
between stress, mood, stress hormones and adiponectin. Therefore
the aim of the present study was to examine the relationship between
adiponectin, psychological stress and mood, in younger (Study 1) and
older (Study 2) women, as well as stress-related hormones (available
in Study 1).
Methods
Participants
Study 1: Premenopausal women
Fifty-two healthy, premenopausal women (all mothers), aged
between 20 and 50 years, were recruited through their child's health
care professional in clinics in Bay Area hospitals, or by public posting.
The women were admitted to a General Clinical Research Center
(GCRC) for a study on caregiving and health, during the ﬁrst 7 days of
the follicular phase, if not on oral contraceptives. Women taking oral
contraceptives came to the GCRC during placebo days.
To capture a range of stress levels, the sample included both
mothers of chronically ill children and a control group of mothers
with healthy children. All women had at least one biological child.
Forty-one mothers had children with a chronic disorder (such as
neurological, a gastrointestinal disorder, or a pervasive development
disorder), and 21 had healthy children. The study protocol was
approved by the Institutional Review Board of the University of
California, San Francisco. Written, informed consent was obtained
from all participants The participants were free of any acute or chronic
health condition by self-report, with the exception of controlled
hypertension (n=2) and controlled hypothyroidism (n=1). Partici-
pants did not consumemore than seven alcoholic beverages per week,
or exercise more than one hour a day. They refrained from alcohol the
day before the study. The measures collected are listed below.
Study 2: Postmenopausal women
A second sample comprised 63 healthy, postmenopausal women
aged between 51 and 79, who also were recruited in the Bay Area of
California through ﬂyers in the community, newspaper advertisements
and an Internet homepage (Craigslist). This mainly white sample
(80.9%) also included one Black, one Hispanic/Latina and seven Asian
women. Similarly to the ﬁrst sample, a wide range of stress levels wascaptured by including women giving care to a relative diagnosed with
dementia as well as non-caregiving women.
Exclusion criteria were similar as in Study 1, and included the
presence of major medical conditions such as heart disease, cancer or
diabetes, use of medications containing agents known to affect stress
hormone levels and regular smoking. The study protocol was
approved by the Institutional Review Board of the University of
California, San Francisco. Written, informed consent was obtained
from all participants. We were able to obtain the same battery of
measures from a subsample of these women (n=25) 1 year later for
prospective data analysis.
Psychological assessments (Study 1 and Study 2)
Perceived stress levels were assessed by means of the Perceived
Stress Scale (PSS) (Cohen et al., 1983). The PSS is a 10-item scale that
measures the degree to which situations in an individual's life are
appraised as stressful.
Subjective Positive and negative affect was measured with the
Positive and Negative Affect Schedule (PANAS) (Watson et al., 1988).
Positive affect refers to positive states such as enthusiastic, active,
attentive, strong or alert and negative affect refers to a general
dimension of subjective distress, encompassing a variety of aversive
mood states such as anger, contempt, disgust, fear and nervousness. In
addition, a SCID interview was conducted for women in Study 2, by
trained interviewers to assess major depression and dysthymia.
Anthropometric data
In both studies, weight was measured using a balance beam scale,
and height was measured with a stadiometer. Body mass index (BMI)
was calculated as weight (kg)/height (m)2. In Study 2, trunk fat was
measured at baseline and 12 months later using a Holographic DEXA-
Scan at the UCSF CTSI clinic.
Stress-responsive hormones (Study 1 only)
A 12 h nocturnal urine sample (20:00 h to 08:00 h) was collected
from a subsample of 52 participants and assayed for stress hormones
(free urinary cortisol, epinephrine, and norepinephrine) and creati-
nine. The selection of the subsample was based on the amount or
urine collected. Participants who had collection volumes less than 300
ml (n=4) were determined to have incomplete collections and their
urinary hormone values were excluded from analyses, as done in
other studies with 12 h urine collections (Greendale et al., 1999).
Urine samples were kept in a cooler with ample ice blocks for the
duration of the collection. Samples were picked up immediately the
next morning. Aliquots were frozen at −80 °C until analysis.
Urinary epinephrine and norepinephrine were assayed with kits
provided by American Laboratory Products Company (Alpco), Wind-
ham, NH. The sensitivity was 0.33 and 1.33 ng/ml, respectively, for
epinephrine and norepinephrine. For epinephrine the intra- and
interassay coefﬁcients of variation (CV's) were 7.2 and 15.4%,
respectively. For norepinephrine, the intra- and interassay CV's were
10.2 and 15.0%, respectively. Cortisol was measured by a radioimmu-
noassay. The sensitivity of the method is 10 nml. Intra- and interassay
CV's were 9.3 and 5.4%, respectively. Creatinine was measured
spectrophotometrically by the Jaffe reaction at 490 nm after extrac-
tion of the samples with ethyl ether to remove interfering substances.
Blood sample collection and processing
Study 1
Blood sampling took place at Oakland Children's Hospital Pediatric
Clinical Research Center. Participants fasted for 10 h, starting from
dinner the previous night. At 0800 in the morning subjects had a
fasting blood draw. Blood samples were centrifuged, aliquoted and
Table 1
Pearson correlations between adiponectin and stress-related variables in premeno-
pausal women (Study 1).
Zero-order
correlations
Partial correlations
(adjusted for age and BMI.
Additionally, for urinary hormones,
adjusted for creatinine)
Psychological state
Negative mood (n=56) −0.40⁎ −0.29⁎
Positive mood (n=56) 0.07 0.11
Perceived stress (n=60) −0.07 −0.23
Hormones
Urinary epinephrine (mg/ng)
(n=38)
−0.34⁎ −0.42⁎
Urinary cortisol (nml)
(n=38)
−0.06 0.06
Urinary norepinephrine (mg/ng)
(n=37)
−0.24 −0.23
Serum DHEA_S (ng/ml) (n=61) −0.26⁎ −0.25⁎
⁎ pb0.05 (two-tailed).
Fig. 1. Scatterplot of cross-sectional association between negative mood and plasma
adiponectin levels (Study 1). pb0.05.
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assayed for adiponectin (μg/ml) and DHEA_S (ng/ml).
DHEA_S concentrations were measured by Enzyme Immuno Assay
(EIA), and free testosterone by 125I-based radio immune assays (RIA)
with kits obtained from Diagnostic Systems Laboratories, Inc. (DSL,
Webster, TX) (Miller et al., 2004).
Plasma adiponectin concentrations were measured using a radio-
immunoassay for human adiponectin (Millipore, MA) at the UC Davis
lab of Dr. Peter Havel. The assay utilizes 125I-labeled adiponectin and an
anti-adiponectin rabbit antiserum to measure adiponectin concentra-
tions by the double antibody/PEG technique. Standards over the range
of 1–200 ng/ml were prepared using recombinant human adiponectin.
All plasma samples were diluted 1:200 yielding an effective range of
0.2–40 µg/ml. The intra-assay and interassay coefﬁcients of variation of
adiponectin concentrations in this laboratory in the rangeof 3–25 µg/ml
are 5.1–7.2% and 9.1–12.1%, respectively. Adiponectin levels are
relatively stable during the daytime (Swarbrick and Havel, 2008).
Study 2
Blood draws took place at the CTSI General Clinical Research
Center at the University of California, San Francisco. Participants
fasted for 8 h starting frommidnight and with the actual fasting blood
draw being performed at 8 o’ clock in the morning. Blood samples
were centrifuged, aliquoted and stored in polypropylene vials at
−20 °C until analysis. Adiponectinwas assayed in Dr. Havel's lab, as in
Study 1 above.
Statistical analysis for both studies
Statistical analysis was performed with SPSS software (version 15.0,
SPSS Inc., Chicago, IL, USA). Results are reported as mean values±
standard errors (SE). Differences between caregivers and non-care-
givers were assessed by analysis of variance (ANOVA). Adiponectin
data of Study 2 were not normally distributed and were therefore log-
transformed.
Zero-order Spearman correlation coefﬁcients were used to assess
associations between plasma adiponectin with psychological and
hormonal variables.
Partial correlations were conducted to control for BMI and age.
Oral contraceptives, smoking, and age were tested as potential
covariates and since they were not related to adiponectin they were
not included. In the longitudinal analysis (Study 2) we controlled for
change in BMI from baseline to 12 month follow up as well as plasma
adiponectin level at baseline. A p value of b0.05, two tailed, was
considered signiﬁcant.
For Study 2, we performed a hierarchical linear regression to assess
the contribution of negative mood to adiponectin at 12 months above
and beyond baseline adiponectin, and change in BMI from baseline to
12 months. We entered baseline adiponectin and change in BMI in
step 1, and negative mood in step 2. To adjust for the skewed
distribution of adiponectin, we performed natural logarithmic
transformations.
Results
Study 1
Fifty-two premenopausal women with complete data were included
in the statistical analysis, with age ranging from 19 to 50 years (M age=
38.16, SD=6.24; M BMI=26.71, SD=6.73). As expected, adiponectin
was correlated with BMI (r=−0.40, p=0.001). Therefore correlations
are shown as raw and adjusted for BMI and age (Table 1). In this cross-
sectional approach negative mood was inversely correlated with plasma
adiponectin, independent of BMI (r=0–0.30, pb0.05). As demonstrated
in Fig. 1, plasmaadiponectin levelswere consistently low forwomenwith
the strongest negative mood ratings. In contrast to women with highnegative mood ratings, women with the lowest negative mood ratings
show a greater range of adiponectin levels.
Adiponectin was also signiﬁcantly and inversely related to
nocturnal urinary epinephrine ( r=0–0.46, p≤0.005; Fig. 2) inde-
pendent of BMI, and to serum DHEA-S ( r=−0.27, pb0.005), an
inverse, and a non-signiﬁcantly correlation with norepinephrine.
Adiponectin was not associated with perception of life stress or
urinary cortisol. Adiponectin was not related to positive affect.
Positive affect, however, was negatively related to perceived stress.
Study 2
Forty-eight postmenopausal women had complete data and were
included in statistical analysis. They had an age range between 51 and
79 years (M age 61.87, SD=6.51). Their mean BMI was 26.72
(SD=5.49). Postmenopausal women reported signiﬁcantly less
negative mood compared to premenopausal women (M negative
mood=8.8, SD=9.4 vs. M negative mood=19.2, SD=10.9, respec-
tively, pb0.05). The two groups also had signiﬁcantly different
baseline adiponectin concentrations (M adiponectin=7.2,
SD=3.2 ng/ml for premenopausal vs. M adiponectin=13.2,
SD=5.2 ng/ml in postmenopausal women). BMI was not signiﬁcantly
different between groups (M BMI=26, SD=6.7 in premenopausal vs.
M BMI=24, SD=5.3 in postmenopausal women).
As expected, adiponectin was inversely, but not signiﬁcantly
related to BMI (r=−0.24, p=0.083). In postmenopausal women, the
cross-sectional association between adiponectin and mood was not
signiﬁcant (r=0.04, p=0.78). However, prospectively there was a
Fig. 2. Scatterplot of relation between adiponectin and urinary epinephrine (Study 1).
pb0.05.
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and plasma adiponectin levels obtained in the follow up sample
(n=28) 12 months later, adjusting for change in BMI as well as
baseline age and adiponectin concentrations (partial r=−0.48,
p=0.002), showing women with high negative mood at baseline
have decreases in adiponectin 1 year later.
In a 3 step hierarchical linear regression, baseline adiponectin
accounted for 87% variance in step 1, BMI change for an additional 2% in
step 2, and in the last step, negative mood accounted for an additional
4.7% of the variance in adiponectin 1 year later (T=− 4.5, p=0.001).
It is remarkable that decreases in adiponectin were independent of
changes in body fat. It is reasonable that negative mood might
decrease adiponectin through increasing not just total fat but in
particular abdominal fat, since larger abdominal fat cells produce less
adiponectin. Therefore, we also tested this relationship while
controlling for abdominal fat changes, as measured by a DEXA scan
(using trunk fat). This inverse relationship between negative mood
scores at baseline and adiponectin changes at 12 month follow up,
remained signiﬁcant even after controlling for change in trunk fat
from baseline to 12 months (r=−0.46, p=0.002).
Lastly, as a secondary analysis, we also analyzed the relation between
depression category at baseline, as assessed by the SCID, and adiponectin.
There were 8 women with current depression, and 2 with dysthymia,
which were not enough to analyze separately, so we combined these
women into one group.We tested whether adiponectin was different by
group, adjusting for BMI. At baseline, women with a depressive disorder
(depression or dysthymia, n=10) had signiﬁcantly lower adiponectin
than the group without a depressive diagnosis (M adiponectin=9.96,
SD=1.5 vs. 14.0, SD=0.73, F(2,53)=5.6, pb0.02). A year later, both
groups had decreased with similar magnitude, by 1 ug/dl.
Discussion
We found that adiponectinmay be responsive to negativemood and
adrenergic tone, at least in terms of nocturnal epinephrine levels. There
is converging evidence that negative affect and stress create suscepti-
bility to physical illness, such as to the common cold, cardiovascular
disease and premature mortality (Brummett et al., 2001; Cohen et al.,
1991; Stewart-Brown, 1998). Underlying mechanisms such as chronic
inﬂammation (Chrousos, 2000a) and cortisol dysregulation contribute
to metabolic disease (Chrousos, 2000a), but other pathways, such as
changes metabolic peptides, have not yet been well elucidated.
In a cross-sectional approach, premenopausal women scoring
highest on a scale that measures subjective negative affect show the
lowest plasma adiponectin concentrations, controlling for BMI. Having
low levels of negative mood, however, was not related to higher
adiponectin but rather to a wide range of adiponectin concentrations.
Similarly, in both studies, there was no association between positivemood with higher adiponectin. These ﬁndings suggest speciﬁcity for
high levels of negative mood as one factor potentially inﬂuencing
adiponectin level in humans. In the study of elderly women,
surprisingly, negative mood was not associated with adiponectin.
However, we also had measured diagnoses of depressive disorders
(current major depression or dysthymia). This index of more severe
negative mood—having a depressive disorder—was associated with
signiﬁcantly lower levels of adiponectin. This supports earlier ﬁndings
linking major depression to lower adiponectin, when comparing 32
participants with depression to controls (Leo et al., 2006).
To further address the question of temporal sequencing, we
analyzed data of a sub-sample of elderly women over 1 year, and
found a signiﬁcant negative correlation between negative mood at
baseline and lower plasma adiponectin levels 1 year later, covarying
baseline adiponectin. This relationship was independent of changes in
BMI, age or trunk fat.
Although the study was not designed to compare effects of stress
and depression, it is notable that neither measure of stress—objective
stress, as measured by caregiver group, and perceived stress—were
related to adiponectin, whereas both measures of negative affect
(negative mood as measured by the PANAS, and having a diagnosis of
depression or dysthymia) were both related to lower adiponectin.
Adiponectin may be more tied to the neurobiology of depression, as
the underlying physiological correlates of stress and depression are
different (in complex and poorly deﬁned ways).
Alternatively, negative mood may represent a more stable or
traitlike emotional state, compared to perceived stress, which more
closely reﬂects changing objective environmental demands. Although
caregiving status represents a chronic stressor, there are nevertheless
varying levels of stress and negative mood within the caregiving
group, which may be why individual differences in mood rather than
group status are a more important factor here. It would have been
helpful to assess negative mood with repeated measures over time to
get a more traitlike measure.
Catecholamines are known to play a major role in fuel homeostasis
and in counteracting insulin action (Rupp and Maisch, 2003), but their
inﬂuence on adiponectin has scarcely been investigated. To our
knowledge only one study investigated the effect of catecholamines
on plasma adiponectin levels in vivo in mice (Delporte et al., 2002). In
human and mouse adipose tissue a signiﬁcant decrease of adiponectin
mRNA was found after culture with ß-adrenergic agonists or cAMP
(Delporte et al., 2002). Adrenergic dysregulation is commonwith stress
and many psychiatric disease states and may further predispose to low
adiponectin. Catecholamines may be the physiological substrate
explaining the relationship of adiponectin and negative mood.
DHEA-S was negatively correlated with plasma adiponectin con-
centrations. Postulated consequences of low DHEA include insulin
resistance (Schriock et al., 1988) andobesity (Nestler et al., 1988).While
elevated circulatingDHEA-S concentrationshavebeen associatedwith a
reduced incidence of cardiovascular disease inmen (Barrett-Connor and
Ferrara, 1996), relationships may be the opposite in women: While
DHEA-S may have neuroprotective (Juhasz-Vedres et al., 2006) and
anxiolytic (vanNiekerk et al., 2001) features on the one hand, increased
DHEA-S concentrations also have been found to be correlated with
increased abdominal fat in premenopausal women, and in postmeno-
pausal women, with glucose intolerance (Barrett-Connor and Ferrara,
1996) and cardiovascular disease (Williams et al., 1993). If high levels of
DHEA-S promote metabolic disease in women (Barrett-Connor and
Ferrara, 1996; Williams et al., 1993), the present study suggests that
DHEA-S might act in part through affecting adiponectin levels.
In the present study the relationship between negative mood and
adiponectin does not seem to be mediated by cortisol levels, as there
was no correlation between adiponectin levels and cortisol. However,
true mediation must be assessed over time and snap shot measures of
cortisol do not closely reﬂect past history of HPA axis activity. Other
ﬁndings on the association between cortisol and adiponectin are
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consensus sequences for glucocorticosteroid receptor binding, adipo-
nectin could potentially be modiﬁed by environmental stress
(Comuzzie et al., 2001). Further, it has been demonstrated that
dexamethasone, a synthetic corticosterone decreases adiponectin
gene expression (Fasshauer et al., 2002). These results were obtained
from cell culture research and it needs to be clariﬁed whether this
holds for plasma concentrations in vivo as well. However, others
found a positive correlation between fasting morning cortisol and
circulating adiponectin concentrations (Fernandez-Real et al., 2003),
supporting the role of adiponectin in anti-inﬂammatory feedback.
Urinemeasures average over time and thus obscure any variance from
dysregulation of the diurnal peak, nadir, or morning waking response.
Further studies are needed to speciﬁcally examine speciﬁc aspects of
HPA axis dysregulation in relation to adiponectin.
Since adiponectin levels are associatedwith certain risk factors of the
metabolic syndrome such as obesity, diabetes mellitus and reduced
insulin sensitivity, these ﬁndings raise the possibility that adiponectin
may in part mediate the relationship between depression, negative
mood, and metabolic health (Lihn et al., 2005). Other authors have
shown a difference in adiponectin concentrations with age (Gavrila
et al., 2003). This difference has been attributed to changes in body
composition. In the present study adiponectin concentrations were
related to BMI in both groups and groupswere not different concerning
BMI. This suggests, in accordance with others (Jurimae and Jurimae,
2007), that menopausal status, rather than body composition has a
major inﬂuence on the difference in adiponectin concentrations
between premenopausal and postmenopausal women.
There are many limitations to these initial studies. The samples
included women only, and it is unknown if these relationships would
have been found in men. Due to a small number of participants
examined in the follow up study at 12 months, we are limited in our
conclusions Many correlations were performed with relatively small
samples. Further studies are needed to replicate the prospective
relationship between negative mood and adiponectin levels found in
the present study. Negative mood may work through behaviors. For
example, it is linked to changes in diet, either increased intake or
increase of certain sugars that are linked to decreased adiponectin, and
dietary analyses as well as insulin sensitivity assessment would have
been helpful. It would have been helpful to examine the roles of
inﬂammatory markers as possible mediators in the relationships
between negative mood with adiponectin. Nevertheless, this is to our
knowledge the ﬁrst study demonstrating links between depressed and
negative affect with adiponectin. These factors might prove to be a
helpful new target for the prevention of features of the metabolic
syndrome.
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